Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile

Autor: Ascierto, Paolo A., Di Giacomo, Anna M., Chiarion Sileni, Vanna, Queirolo, Paola, Spagnolo, Francesco, De Galitiis, Federica, Cognetti, Francesco, Mandalà, Mario, Guidoboni, Massimo, Rinaldi, Gaetana, Depenni, Roberta, Consoli, Francesca, Troiani, Teresa, Guida, Michele, Marconcini, Riccardo, Ferrucci, Pier F., Strippoli, Sabino, Fava, Paolo, Merelli, Barbara, Simeone, Ester, Di Guardo, Lorenza, Giannarelli, Diana, Maio, Massimo, Quaglino, Pietro, Del Vecchio, Michele

Publikováno v: In European Journal of Cancer September 2023 191

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The effect of COVID-19 emergency in the management of melanoma in Italy

Autor: Anichini, A., Asero, S., Bersanelli, M., Caraco, C., De Giorgi, V., Di Giacomo, A. M., Feliciani, C., Ferraresi, V., Ghiorzo, P., Grimaldi, A. M., Guida, M., Mandala, M., Massi, D., Mocellin, S., Palmieri, G., Patuzzo, R., Pizzichetta, M. A., Ricci, R., Rossi, G., Quaglino, P., Queirolo, P., Senetta, R., Stanganelli, I., Tucci, M.

Publikováno v: Dermatology Reports, Vol 13, Iss 1 (2021)
Dermatology Reports

The COVID-19 pandemic has severely hampered the functioning of any health system, absorbing a considerable amount of resources and with the threat of widespread infection in the health services. The present survey has been carried out in Italy to eva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab76b17c7d04caa2e783055b46cd0b90
https://hdl.handle.net/2318/1890616

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Autor: Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. -J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., Robert, C., Eggermont, A. M. M., EORTC Melanoma Group, Lesimple, T., Maio, M., Linette, G., Mortier, L., Svane, I. M., Schachter, J., Brown, M., Hersey, P., Barrow, C., Kudchadkar, R., Dutriaux, C., Song, X., Quaglino, P., Queirolo, P., Meier, F., Stroyakovskiy, D., Guillot, B., Romero, P. L. O., Bastholt, L., Garbe, C., Grange, F., Mohr, P., Algazi, A., Bechter, O., Hernberg, M., Loquai, C., Meiss, F., Chiarion Sileni, V., Bar-Sela, G., Fitzharris, B., Saiag, P., Arnault, J. -P., Simon, J. -C., Stephens, R., Baurain, J. -F., Lebbe, C., Combemale, P., Dummer, R., Hauschild, A., Parente, P., Yamazaki, N., Milhem, M., Leccia, M. -T., Geoffrois, L., Kretschmer, L., Dunwoodie, E., Walker, J., Lotem, M., Hendler, D., Mackiewicz, A., Sekulovic, L., Dzienis, M., Hospers, G. A. P., Siano, M., Hassel, J., Corrie, P., Passos, M. -J., Levin, M., Hoeller, C., Machet, L., Hallmeyer, S., Waterston, A., Descamps, V., Kiecker, F., Aarts, M., Schmidt, H., Raimundo, A., Nyakas, M., Lacour, J. -P., Berking, C., Ferrucci, P. F., Jameson, M., Kim, K., Yokota, K., Kerger, J., Aubin, F., Groenewegen, G., Kapiteijn, H., Boehncke, W. -H., Utikal, J., Casasola, R., Marshall, E., Ferraresi, V., Richtig, E., Matkovic, S., Inozume, T., Crook, T., Mcneil, C., Kiyohara, Y., Avril, M. -F., Hein, R., Terheyden, P., Nathan, P., Aoi, J., Skytta, T., Jouary, T., Takenouchi, T., Straume, O., Martins, C., Mukhametshina, G.

Publikováno v: Lancet. Oncology, Vol. 22, No 5 (2021) pp. 655-664
EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 655-664 . https://doi.org/10.1016/S1470-2045(21)00081-4
Lancet Oncology, 22, 5, pp. 655-664
The Lancet Oncology, 22(5), 655-664. Lancet Publishing Group
Lancet Oncology, 22, 655-664
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.655-664. ⟨10.1016/S1470-2045(21)00081-4⟩
The Lancet Oncology, 22(5), 655-664. ELSEVIER SCIENCE INC

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80dc0ff7069bff303dade337b8effb2d
https://archive-ouverte.unige.ch/unige:159804